Table 3. Grade ≥3 TEAEs and serious TEAEs with ≥10% incidence.

Adverse events		Niraparib 300 mg (n=20)
Grade ≥3 TEAEs		17 (85.0)
	Anemia	11 (55.0)
	Platelet count decreased	6 (30.0)
	Neutrophil count decreased	4 (20.0)
	Lymphocyte count decreased	2 (10.0)
	Weight decreased	2 (10.0)
	White blood cell count decreased	2 (10.0)
Serious TEAEs observed in ≥10% of patients		8 (40.0)
	Anemia	2 (10.0)
	Platelet count decreased	2 (10.0)

Values are presented as number (%) of patients. TEAEs were defined as adverse events that occurred after administration of the first dose of study drug and are shown by MedDRA Preferred Term.

MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event.